Oncology

Review top news and interview highlights from the week ending July 15, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

SCG101 will be evaluated in trials across China, Singapore, and the US.

The chief program officer of the Alliance for Cancer Gene Therapy discussed the work the nonprofit is doing.

The associate director of Research at Senti Biosciences discussed the company's research on using logic-gated CAR-NK cells for the treatment of AML and solid tumors.

A phase 1 trial has completed enrollment in its first cohort and is now enrolling the second.

The chief scientific officer at TScan Therapeutics discussed the company’s SafetyScan technology.

Legend Biotech seeks to prioritize other product candidates in its pipeline.

The senior director and clinical program leader, Translational Clinical Oncology at Novartis Institutes for BioMedical Research, discussed new data from the phase 1 study.

The professor of medicine and University of Minnesota Medical School discussed the advantages and unmet needs of natural killer cells in oncology.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The research fellow from Harvard Medical School discussed blocking IFNg as a potential approach to reduce toxicities.

The instructor of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania discussed his thoughts on the potential of targeting mutant KRAS with immunotherapy.

The associate professor at Fred Hutch Cancer Center discussed data presented at the EHA 2022 Congress.

Review top news and interview highlights from the week ending July 1, 2022.

The chief of cancer immunotherapy at Rutgers Cancer Institute discussed clinical results with different cell therapy approaches.

The scientist at A2 Biotherapeutics discussed the company’s dual-receptor Tmod technology.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The acting chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed the evolution of cell therapies in the past decade.

A clinical trial evaluating MB-106 in WM is planned under Mustang Bio's new IND.

The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed data from real-world experience studies.

The approval builds off of liso-cel's (Breyanzi) previous indication for third-line or later treatment in LBCL.

Review top news and interview highlights from the week ending June 24, 2022.

The phase 1/2 OVATION 2 study is expected to complete enrollment by the third quarter of this year.

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed cilta-cel and upcoming cell therapies.